Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

Phase 4 Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Ramiprin Tab. in Essential Hypertension

The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension

Inclusion Criteria:

• mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg)

Exclusion Criteria:

• 180mmHg≤SBP
• If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings
• If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings
• impaired hepatic function
• imapaired renal function
• angioedema
• aortic valvular stenosis or obstrcutive ejection disorder
• primary hyperaldosteronism
• renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis
• severe respiratory disease
• congestive heart failure( New York Association functional class Ⅲ or Ⅳ)
• malignant hypertension
• labile angina pectoris or myocardial infarction in the last 3 months before study entry